Abstract:BACKGROUND: Antigen sparing and cross-protective immunity are regarded as crucial in pandemic influenza vaccine development. Both targets can be achieved by adjuvantation strategy to elicit a robust and broadened immune response. We assessed the immunogenicity of an inactivated H5N1 whole-virion vaccine (A/Vietnam/1194/2004 NIBRG-14, clade 1) formulated with emulsified nanoparticles and investigated whether it can induce cross-clade protecting immunity.METHODOLOGY/PRINCIPAL FINDINGS: After formulation with PELC, a proprietary water-in-oil-in-water nanoemulsion comprising of bioresorbable polymer/Span(R)85/squalene, inactivated virus was intramuscularly administered to mice in either one-dose or two-dose schedule. We found that the antigen-specific serum antibody responses elicited after two doses of non-adjuvanted vaccine were lower than those observed after a single dose of adjuvanted vaccine, PELC and the conventional alum adjuvant as well. Moreover, 5 microg HA of PELC-formulated inactivated virus were capable of inducing higher antibodies than those obtained from alum-adjuvanted vaccine. In single-dose study, we found that encapsulating inactivated virus into emulsified PELC nanoparticles could induce better antibody responses than those formulated with PELC-adsorbed vaccine. However, the potency was rather reduced when the inactivated virus and CpG (an immunostimulatory oligodeoxynucleotide containing unmethylated cytosine-guanosine motifs) were co-encapsulated within the emulsion. Finally, the mice who received PELC/CpG(adsorption)-vaccine could easily and quickly reach 100% of seroprotection against a homologous virus strain and effective cross-protection against a heterologous virus strain (A/Whooper swan/Mongolia/244/2005, clade 2.2).CONCLUSIONS/SIGNIFICANCE: Encapsulating inactivated H5N1 influenza virus and CpG into emulsified nanoparticles critically influences the humoral responses against pandemic influenza. These results demonstrated that the use of PELC could be as antigen-sparing in preparation for a potential shortage of prophylactic vaccines against local infectious diseases, in particular pandemic influenza. Moreover, the cross-clade neutralizing antibody responses data verify the potential of such adjuvanted H5N1 candidate vaccine as an effective tool in pre-pandemic preparedness.

Effects of Different CpG Oligodeoxynucleotides with Inactivated Avian H5N1 Influenza Virus on Mucosal Immunity of Chickens.

The Immunomodulatory Functions of Various CpG Oligodeoxynucleotideson CEF Cells and H 9 N 2 Subtype Avian Influenza Virus Vaccination.

The Immunogenicity of CO-expressing Plasmid and Fusion Genes Plasmid Containing IBDV VP2/4/3 and ChIL-18 Genes

Enhancement of the Immunogenicity of DNA Vaccine Against Infectious Bursal Disease Virus by Co-Delivery with Plasmid Encoding Chicken Interleukin 2.

Comparison of 3 kinds of Toll-like receptor ligands for inactivated avian H5N1 influenza virus intranasal immunization in chicken.

Efficacy of CpG-ODN and Freund's immune adjuvants on antibody responses induced by chicken infectious anemia virus VP1, VP2, and VP3 subunit proteins

Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken.

Effect of intranasal immunization with inactivated avian influenza virus on local and systemic immune responses in ducks.

A novel combined adjuvant strongly enhances mucosal and systemic immunity to low pathogenic avian influenza after oral immunization in ducks.

Immune Enhancement of CpG ODN on LaSota Lived Vaccine against Newcastle Disease in Chickens

Efficacy of DNA vaccines against infectious bursal disease virus in chickens enhanced by coadministration with CpG oligodeoxynucleotide.

Efficacy of an inactivated influenza vaccine adjuvanted with Toll-like receptor ligands against transmission of H9N2 avian influenza virus in chickens

Emulsified Nanoparticles Containing Inactivated Influenza Virus and CpG Oligodeoxynucleotides Critically Influences the Host Immune Responses in Mice

Effects of intranasal immunization with inactivated avian influenza virus in combination with adjuvants on the antibody secreting cells in pigeon respiratory tract

Effect of Intranasal Immunization with Inactivated Avian Influenza Virus and Adjuvant on the Antibody Secreting Cells in Chicken Respiratory Tract

Induction of a protective immune response against Chlamydophila psittaci in SPF chicken following vaccination with OMP-1 DNA and CPG oligonucleotides as an adjuvant

Intranasal immunization with O-2'-Hydroxypropyl trimethyl ammonium chloride chitosan nanoparticles loaded with Newcastle disease virus DNA vaccine enhances mucosal immune response in chickens

Improved cellular immune response induced by intranasal boost immunization with chitosan coated DNA vaccine against H9N2 influenza virus challenge

Effect of oral immunization with inactivated avian influenza virus and adjuvant polyethyleneimine on the immune response and growing development in chicken

The preliminary screening of different adjuvants in transcutaneous immuniza-tion with inactivated human highly pathogenic avian influenza vaccine

Determining the Protective Efficacy of Toll-Like Receptor Ligands to Minimize H9N2 Avian Influenza Virus Transmission in Chickens